Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 3Medulloblastoma 3Rhabdomyosarcoma 2Rhabdoid Tumor 2Meningeal Carcinomatosis 2Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Retinoblastoma 1Pinealoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Meningeal Neoplasms 1Hepatoblastoma 1Ependymoma 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 26Magnetic Resonance Spectroscopy 19Etoposide 12Cyclophosphamide 12Radiotherapy 11Bevacizumab 10Filgrastim 9Biopsy 8Carboplatin 7X-Rays 6Thiotepa 6Specimen Handling 6Phantoms, Imaging 6Cisplatin 6Carmustine 6Nuclear Medicine Department, Hospital 5Nivolumab 5Irinotecan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4olaparib 3etoposide phosphate 3Vincristine 3Surveys and Questionnaires 3Lapatinib 3Gadolinium DTPA 3Azacitidine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × omburtamab I-131 × CNS × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡